Table 4 |
|||
|
Comparison between HER2 amplified and non-amplified primary breast cancers |
|||
|
Characteristic |
n amplified (percentage) |
n not amplified (percentage) |
p |
|
|
|||
|
pT category |
|||
|
pT1 |
3 (10.3) |
26 (89.7) |
0.31 |
|
pT2 |
13 (26.5) |
36 (73.5) |
|
|
pT3 |
2 (28.6) |
5 (71.4) |
|
|
pT4 |
2 (14.3) |
12 (85.7) |
|
|
Not available |
2 (33.3) |
4 (66.7) |
|
|
Nodal status |
|||
|
Positive |
14 (21.9) |
50 (78.1) |
0.44 |
|
Negative |
4 (14.8) |
23 (85.2) |
|
|
Not available |
4 (28.6) |
10 (71.4) |
|
|
Histologal type |
|||
|
Ductal |
20 (24.4) |
62 (75.6) |
0.30 |
|
Lobular |
2 (16.7) |
10 (83.3) |
|
|
Ductulo-lobular |
0 |
10 (100) |
|
|
Medullary |
0 |
1(100) |
|
|
Nuclear grade |
|||
|
1 |
0 |
7 (100) |
0.01 |
|
2 |
4 (9.8) |
37 (90.2) |
|
|
3 |
18 (32.7) |
37 (67.3) |
|
|
Not available |
0 |
2 (100) |
|
|
|
|||
|
HER2, gene encoding human EGF-like receptor 2. |
|||
|
Tapia et al. Breast Cancer Research 2007 9:R31 doi:10.1186/bcr1676 |
|||
